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Selenium nanoparticles loaded with an anticancer molecule offer a new strategy for cancer treatment. In the
current study, anisomycin-loaded functionalized selenium nanoparticles (SeNPs@Am) have been made by
conjugating anisomycin to the surface of selenium nanoparticles to improve anticancer efficacy. The prepared
nanoparticles were fully characterized by transmission electronic microscopy, energy dispersive X-ray spectroscopy,
Fourier-transformed infrared spectroscopy, and X-ray photoelectron spectroscopy. The results showed that
anisomycin was successfully conjugated with selenium nanoparticles. The size of particles could be effectively
regulated through altering the reaction concentrations of sodium selenite and anisomycin. The SeNPs@Am particles
(56 nm) exhibited the greatest capacity for cellular uptake. The further study showed that SeNPs@Am entered
human hepatocellular carcinoma HepG2 cells in a dose or time-dependent manner via macropinocytosis and
clathrin-mediated endocytosis pathways. SeNPs@Am significantly inhibited HepG2 cell proliferation with the low
cytotoxicity against normal cells, and dramatically precluded the aggression and migration of HepG2 cells. It also
arrested the cell cycle progression at the G0/G1 phase through the activation of the cyclin-dependent kinase
inhibitors with inhibition of CDK-2 and ICBP90, and induced the cell apoptosis through activating the caspase
cascade signaling in HepG2 cells, markedly superior to anisomycin alone. The findings indicate that SeNPs@Am may
be a promising drug for hepatocellular carcinoma.
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Hepatocellular carcinoma (HCC) is one of the most
common malignancies worldwide [1]. Owing to its high
metastatic potential and resistance to traditional drugs,
efficient chemotherapy has become one of the great
challenges in clinical treatment [2]. The traditional
chemotherapy is usually associated with several short-
comings, such as nonselective distribution of drugs, drug
toxicity, and undesired side effects [3]. In addition, most
of current anticancer agents usually have short circula-
tion half life and poor aqueous solubility, which hampers
therapeutic efficacy of chemotherapy [4, 5]. Thus, new
strategies to improve treatment are urgently required.
Application of bionanomaterials in the biomedical field
has the potential to solve these problems [6]. Nanoparti-
cles (NPs) used as drug delivery systems offer a novel* Correspondence: tjliu@jnu.edu.cn; tfyxing@jnu.edu.cn
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cules due to their pharmacokinetics and biodistribution
behaviors [7, 8]. NPs as delivery carriers of anticancer
drugs have enormous merits, including site-specific target-
ing [9], reducing doses, ensuring drug efficacy, minimizing
side effects, protecting drugs against degradation, and
enhancing drug stability [10, 11]. Thus, nanoparticles for
drug delivery have gradually been developed as new strat-
egies for cancer therapy [12, 13].
Selenium (Se), an essential trace element, is one of the
commonly studied materials in cancer therapy [14, 15].
A substantial amount of evidence has suggested that
chemical structures are important determinants of che-
mopreventive activities of selenium compounds [16].
Novel Se nanoparticles (SeNPs) are attracting increasing
attention as potential drug carriers due to their excellent
biological activities [17].
Anisomycin (Am), an antibiotic isolated from Strepto-
myces, can bind with the 60S ribosomal subunit and
prevent peptide bond formation to result in block ofdistributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
ndicate if changes were made.
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functionally inhibiting synthesis of numerous proteins
and DNA [18]. Our previous studies show that anisomy-
cin can significantly suppress cancer cell growth in vitro
[19]. However, high cytotoxicity against normal cells
limits the improvement of anticancer efficacy of aniso-
mycin. In order to achieve enhanced anticancer efficacy
and low cytotoxicity against normal cells, we prepared
functionalized selenium nanoparticles by binding aniso-
mycin with the surface of SeNPs. It has been found that
particle size can affect the effectiveness of cellular uptake
[20]. Herein, tremendous efforts have been made in tai-
loring the size of functionalized selenium nanoparticles
SeNPs@Am by adjusting the reaction concentrations of
sodium selenite or anisomycin, which leads to a series of
SeNPs@Am with size ranging from 56 to 185 nm. The
SeNPs@Am presents good dispersibility, stability, and
superior biocompatibility—all of which are crucial for
biomedical applications. To the best of our knowledge,
no study on the correlation between selenium nanoparti-
cle size and cellular uptake effectiveness has been
reported so far. Thus, we investigated the effect of
SeNPs@Am size on cellular uptake of HepG2 cells. The
data from cellular uptake shows that the maximum up-
take by HepG2 cells occurs at a nanoparticle size of
56 nm. This result will have implications in designing
selenium nanoparticles optimized as anticancer drug
carriers. SeNPs@Am can effectively induce the HepG2
cell apoptosis and preclude the migration of HepG2
cells, and possess great selectivity between HepG2 cells
and normal cells. The underlying action mechanisms of
SeNPs@Am were further investigated in detail. Taken
together, our results suggest that SeNPs@Am can be an
ideal nanodrug for hepatocellular carcinoma.
Methods
Materials
Anisomycin, sodium selenite (Na2SeO3), thiazolylbluete-
trazolium bromide (MTT), and 4′,6-diamidino-2-pheny-
lindole (DAPI), which were of analytical or biological
reagent grade without further purification, were pur-
chased from Sigma. Propidium iodide (PI) and Annexin
V-FITC Kit containing PI were purchased from KeyGen
Biotech, China. Ascorbic acid (Vc) was bought from a
Guangzhou chemical reagent factory. Water used in all
experiments was produced by a Milli-Q water purifica-
tion system (Millipore).
Synthesis of SeNPs with Various Sizes
Na2SeO3 powder and anisomycin were dissolved in
super-purified water to prepare 5 mM Na2SeO3 stock
solution and 20 mM anisomycin solution, respectively.
Aqueous solution containing 20 mM Vc was freshly
made for every experiment. SeNPs with various sizeswere synthesized according to the methods in the lit-
erature with minor modifications. Briefly, 0.0625, 0.125,
0.25, 0.5, and 1 mL of Vc solution were dropwise added
to Na2SeO3 solution (1:1, v/v), and the mixture was
reconstituted to a final volume of 2.5 mL with Milli-Q
water. Then, the mixed solution was stirred for 12 h at
25 °C, and the final concentration of Na2SeO3 was
0.125, 0.25, 0.5, 1.0, and 2.0 mM, respectively. Excess
Na2SeO3 and Vc were removed by dialysis against
Milli-Q water overnight. The pure SeNPs with various
sizes were obtained.Synthesis of SeNPs@Am with Various Sizes
To prepare Am-Vc mixed solution, 12.5, 25, 50, 100,
and 200 μL of Am solution were mixed with 125 μL Vc
solution, respectively. The Am-Vc mixed solution was
dropwise added to 0.125 mL Na2SO3 solution, and the
mixture was reconstituted to a final volume of 2.5 mL
with Milli-Q water. Then, the mixed solution was
stirred for 12 h at 25 °C, and the final concentration of
anisomycin was 0.1, 0.25, 0.5, 1.0, and 2.0 mM. The
prepared nanoparticles SeNPs@Am were purified by
dialysis against super-purified water for 12 h. The pure
SeNPs@Am of 67, 56, 75, 122, and 185 nm in size were
obtained. Finally, the solution was subjected to centri-
fugation at 10,000g for 2 h and freeze-dried. SeNP-
s@Am powder was stored at −20 °C until use. The
SeNPs@Am of 56 nm in size was applied for further
biological studies. Inductively coupled plasma mass
spectrometry (ICP-MS) was applied for determination
of Se concentration. To examine intracellular uptake
and localization of SeNPs@Am in HepG2 cells, it was
labeled with 10 μg of coumarin-6, a fluorescent dye,
through the above-described procedure after addition
of Vc solution.
Various methods were used to characterize properties
of the prepared nanoparticles. Briefly, transmission
electron microscopy (TEM) samples were prepared by
adding the nanoparticles collosol onto a holey carbon
film on copper grids. The TEM images were obtained
on Hitachi (H-7650) at an accelerating voltage at
80 kV. Energy dispersive X-ray spectroscope (EDS) was
used on an EX-250 system (Horiba) to test elemental
composition of the SeNPs@Am. Fourier transform in-
frared spectrometry (FTIR) analysis for all samples was
carried out on an Equinox 55 IR spectrometer. Size dis-
tribution and zeta potential of SeNPs@Am nanoparti-
cles were examined by photon correlation spectroscopy
(PCS) on a Nano-ZS instrument (Malvern Instruments
Limited). X-ray photoelectron spectroscopy (XPS)
measurement was completed on an ESCALAB 250
spectrometer with the monochromatic Al Kα X-ray
radiation (energy 1.49 keV, 500 μm spot size).
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HepG2 and HUVEC-12 cell lines were offered by American
Type Culture Collection (Manassas, VA) and cultured in
RPMI-1640 medium containing 10 % fetal bovine serum
(FBS), 100 units/mL of penicillin, and 50 units/mL of
streptomycin at 37 °C in an incubator containing 5 % CO2.
In vitro Cellular Uptake and Living Cell Imaging of
SeNPs@Am
Intracellular uptake of SeNPs@Am was qualitatively ana-
lyzed as previously described [21]. Briefly, HepG2 cells
were incubated in 6-well plates (80,000 cells/well) at 37 °
C for 24 h. The medium in the well was replaced with
fresh medium containing different concentrations of the
coumarin-6 loaded SeNPs@Am (at the actual concentra-
tions of Se) and incubated for 2 h at 37 °C in a CO2 in-
cubator. At the end of the incubation, the cells were
washed three times with cold phosphate buffered saline
(PBS). Then, the cells were stained with 5 μg/mL of
DAPI for 20 min. After that, the cells were washed three
times with cold PBS, and the intracellular uptake im-
aging of SeNPs@Am was observed under a fluorescent
microscope (Nikon Eclipse 80i). The living cell imaging
of SeNPs@Am was observed using the similar method
mentioned above. For quantitative analysis of cellular
uptake, Se concentrations in the cells after the treatment
were determined by the ICP-MS method. Briefly, the
HepG2 and HUVEC-12 cells were incubated with fresh
medium containing different concentrations of the
SeNPs@Am (at the actual concentrations of Se) for vari-
ous times at 37 °C in a CO2 incubator. Then, the cells
were washed with PBS three times and were lysed after
adding 0.2 M NaOH solution containing 0.5 % Triton X-
100. The product was reconstituted to 1 mL with Milli-
Q H2O and used for ICP-MS analysis. Colocalization of
coumarin-6-loaded SeNPs@Am in HepG2 cells was car-
ried out by separately staining with the lysosomal
marker, Lyso Tracker Red-DND-99 (Sigma-Aldrich Cor-
poration), and nuclear marker DAPI (Sigma-Aldrich
Corporation). Briefly, the cells were cultured in 6-well
plates to 70 % confluence and washed with cold PBS.
Then, they were separately incubated with fresh
complete medium containing Lyso Tracker, DAPI, and
25 μM of the 6-coumarin-loaded SeNPs@Am (at the
actual concentrations of Se) at 37 °C in 5 % CO2 for dif-
ferent times, respectively. Then, the stained cells were
observed under a fluorescence microscope (TE2000-S).
In vitro Drug Release
In a hard glass tube with continuous shaking at 37 °C,
5 mg of SeNPs@Am powder was dissolved in 5 mL PBS
(pH 7.4 and 5.4). At different time intervals, a specific
slight amount of PBS was replaced by an equivalent vol-
ume of PBS. Concentrations of anisomycin wereanalyzed using a HPLC system (Agilent 1100) equipped
with μ-Bondapak C18 (4 × 300 mm) column, and a detec-
tion wavelength was set at 225 nm. Mobile phase is
made by mixing 125 mL of acetonitrile with 875 mL of
0.05 M potassium dihydrogen phosphate buffer solution
(pH 6.0) in a 1-L vacuum flask, and flow rate was set at
1.0 mL/min.
Cellular Uptake Pathway of SeNPs@Am
HepG2 cells were seeded in a 6-well plate at a density of
2 × 105 cells/well and cultured in an incubator with 5 %
CO2 atmosphere. After 24 h, the cells were washed once
with PBS and preincubated in serum-free medium for
1 h with several endocytic inhibitors: 3 mg/mL of NaN3/
50 mM of 2-deoxy-D-glucose (DOG), 2 μg/mL of colchi-
cine, 50 μg/mL of monensin, and 0.45 M of sucrose.
After 1 h of incubation, the medium was replaced with
fresh medium containing 25 μM of SeNPs@Am and fur-
ther incubated at 37 °C in 5 % CO2 for 1 h. Then, the
cells were washed with PBS three times and were lysed
after adding 0.2 M NaOH solution containing 0.5 %
Triton X-100. The cells treated with only SeNPs@Am
(no inhibitor) were used as positive controls. To deter-
mine concentrations of Se, all the samples would be
collected for ICP-MS analysis. Additionally, the cells were
cultured in the medium containing 10 mM NaN3/50 mM
DOG or the complete medium containing SeNPs@Am at
4 °C for 4 h to analyze whether it is energy-dependent.
Uptake (%) was calculated based on the following
equation:
Uptake of SeNPs@Am %ð Þ ¼ ðuptake of SeNPs@Am in presence
of inhibitor= uptake of SeNPs@Am in absence of in hibitorsÞ
 100
Cell Viability Assay
Cell proliferation inhibition was tested by a MTT assay.
HepG2 and HUVEC-12 cells were seeded in 96-well
plates at a density of 6 × 103 and 2 × 103 cells/well at 37 °
C in 5 % CO2 for 24 h, respectively. The cells were ex-
posed to 0.2 mL fresh medium containing SeNPs@Am
(in an equivalent anisomycin concentration level), aniso-
mycin or SeNPs at different concentrations for 48 h.
After that, the previous culture medium was removed
and washed with PBS twice. Then, 20 μL of 5 mg mL−1
MTT solution and 180 μL fresh medium were added to
each well and incubated at 37 °C in 5 % CO2 for 4 h.
The medium with MTT was discarded before 150 μL of
DMSO was added to each well to dissolve the formazan
crystals. An absorbing value of each well at 490 nm was
analyzed by a 680-type microplate reader (Bio-Rad,
Berkeley, CA, USA). Results are expressed as percent-
age of MTT reduction relative to absorbance of control
cells [22].
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HepG2 cells were seeded at a density of 1 × 105 cells/
well on 24-well plates and incubated to 100 % conflu-
ence. The adherent monolayer cells were scratched by
using a micropipette tip and washed twice with PBS to
remove suspended cells. The cells were exposed to
SeNPs@Am (0.2 μM, in an equivalent anisomycin con-
centration level), anisomycin (0.2 μM), or SeNPs (2 μM)
at 37 °C in 5 % CO2. After 6 h, the medium was replaced
with fresh RPMI-1640 with 2 % FBS. The serial images
of scratched monolayer cells were captured at 0 and
24 h by an inverted microscope. Average scratch width
was determined at three random areas, and migration
rate was calculated as follows.
Cell motility %ð Þ ¼ ½1−ðdistance of the wound at 24 h=
distance of the wound at 0 hÞ  100%:
Transwell Migration Assay
Ability of HepG2 cells to migrate was assessed by
transwell-chamber (BD Biosciences, pore size, 8 μm) mi-
gration assay. Briefly, the cells were treated with SeNP-
s@Am (0.2 μM, in an equivalent anisomycin concentration
level), anisomycin (0.2 μM), or SeNPs (2 μM) for 24 h, re-
spectively. Then, the cells at a density of 1 × 105 cells/mL
were re-suspended in 100 μL serum-free medium and
added to the upper chamber, whereas 400 μL medium con-
taining 10 % FBS was applied to the lower chamber. The
cells were next incubated at 37 °C in 5 % CO2 for 24 h, fil-
ter inserts were removed from the wells, and the cells in
the upper chamber were wiped with a cotton swab. The
cells in the lower chamber were fixed with methanol for
10 min and stained with eosin dye for 1 min at room
temperature. Thereafter, the migrating cells in five fields
were randomly captured and counted under a light micro-
scope. Results are expressed as the migration cells in the
experimental group relative to those in the control group.
Inhibition rate of cell migration was calculated according
to the equation, in which Migctrl is from the control cells
that migrate into the lower surface and Migt is from the
treated cells that migrate into the lower surface.





For analysis of cell cycle distribution, the cells were ex-
posed to 0.05, 0.1, and 0.2 μM of SeNPs@Am (in an
equivalent anisomycin concentration level) at 37 °C in
5 % CO2 for 24 h and harvested by centrifugation. The
harvested cells were washed with cold PBS and fixed
in cold 70 % ethanol at −20 °C overnight. Then, the
cells were washed with cold PBS and incubated with0.1 mg/mL RNase, 20 μg/mL PI, and 0.1 % Triton X-
100. DNA content of the cells was analyzed by using a
FACSCalibur flow cytometer with a CellQuest software
(Becton Dickinson, USA).
Annexin V-FITC/PI Staining
To evaluate extent of cell apoptosis, the HepG2 cells
treated with 0.05, 0.1, and 0.2 μM of SeNPs@Am (in an
equivalent anisomycin concentration level) were har-
vested and washed with cold PBS twice. The cells were
re-suspended in 100 μL diluted binding buffer solution
and stained using an Annexin V-FITC Kit containing PI
(KeyGen Biotech, China). They were kept at room
temperature in darkness for 15 min. Before the detec-
tion, 200 μL of diluted binding buffer was added. Finally,
apoptotic proportion of the treated cells was measured
using flow cytometry (FACSCalibur, Becton Dickinson).
TUNEL-DAPI Staining Assay
Apoptotic DNA fragmentation was detected by a TUNEL
assay according to manufacturers’ protocol. Briefly, HepG2
cells were treated with 0.1 and 0.2 μM of SeNPs@Am (in
an equivalent anisomycin concentration level) for 24 h.
They were fixed with 4 % formaldehyde for 10 min and
washed with PBS before permeabilization with PBS con-
taining 0.1 % Triton X-100. Then, TUNEL reaction mix-
ture was added to the cells at room temperature for 1 h.
The cell nuclei were stained with 1 μg mL−1 DAPI for
15 min before the end of the TUNEL staining. Finally, the
stained cells were photographed under a fluorescence
microscope (TE2000-S).
Western Blot Analysis
After being treated with 0.2 μM SeNPs@Am (in an
equivalent anisomycin concentration level), 0.2 μM ani-
somycin, or 2 μM SeNPs, the HepG2 cells were washed
and lysed by a RIPA Lysis Kit (Beyotime Institute of Bio-
technology, China) containing phenylmethylsulfonyl
fluoride (PMSF). The protein concentration of cytosolic
extract was measured with a BCA Protein Assay Kit
(Beyotime). An equal amount of the protein was sepa-
rated by SDS-PAGE and then transferred onto nitrocel-
lulose membranes (Amersham Biosciences, Pittsburgh,
PA, USA). The membranes were blocked with 5 % non-
fat milk at room temperature for 1 h and then washed
three times with tris buffered saline (TBS) containing
0.05 % Tween 20 for 5 min each time. Thereafter, the mem-
branes were probed at 4 °C overnight with primary anti-
bodies, respectively, that included anti-ICBP90, anti-p16,
anti-p21, anti-P-p21(Thr145), anti-p27, anti-P-p27 (Ser10),
anti-P-CDK2 (Thr160), anti-p53, anti-P-p53(Ser20), anti-
E2F1, anti-p73, anti-P-p73 (Tyr99), anti-Rb, anti-P-Rb
(Ser807), and anti-β-actin. Then, the membranes continued
to be incubated with relative second antibodies at room
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hanced chemiluminescence (Cell Signaling Technology,
Inc. USA) according to the manufacturer’s instruction. The
band density was checked by a FluorChem 8000 system
(Alpha Innotech, Santa Clara, CA, USA).
Statistical Analyses
Statistical analyses were performed with SPSS 17.0 soft-
ware (SPSS Inc., IL, US). The results were expressed as
the means ± SD of three independent experiments. Indi-
vidual comparisons were made by one-way ANOVA for
multiple comparison data, and p values less than 0.05
were considered to be statistically different and p values
less than 0.01 to be significantly different.
Results and Discussion
Physical and Chemical Characterization of SeNPs@Am
The particle size impacts on all applications of nanopar-
ticles in biomedicine. Thus, it is very meaningful to con-
trol the size of nanomaterials. It is known that type of
materials, the ratio of reaction substrates, and their final
concentrations influence the size, size distribution, and
chemical composition of particles. In this study, the
functionalized selenium nanoparticle SeNPs@Am with
various sizes were synthesized through adjusting the re-
action concentrations of sodium selenite or anisomycin.
As shown in Fig. 1, an increase in particle size was ob-
served when the reaction concentrations of sodium sel-
enite was increased from 0.125 to 2 mM. Here, 0.5 mM
was chosen as the optimized reaction concentration of
sodium selenite. Figure 2 presents the size graph of
SeNPs@Am synthesized at the different reaction concen-
trations of anisomycin ranging from 0.1 to1.6 mM. TheFig. 1 a Distribution of SeNPs with various size at different reaction concen
SeNPs, respectivelypresence of 0.1~0.4 mM anisomycin significantly de-
creased the particle size to 67, 56, and 75 nm, respect-
ively. However, with increasing the concentration of
anisomycin up to 1.6 mM, the size of SeNPs@Am dra-
matically increased to 185 nm. These datum indicate
that the sizes of functionalized selenium nanoparticle
SeNPs@Am can be regulated by adjusting the reaction
concentrations of sodium selenite and anisomycin. The
SeNPs@Am of 56 nm in size was used as a preferred
nanoscale drug for its suitable size. TEM images of the
prepared SeNPs (Fig. 3a–c) and SeNPs@Am (Fig. 3d–f )
clearly revealed that SeNPs modified with anisomycin
presented a homogeneous and monodisperse spherical
structure with the diameter of approximately 60 nm. In
contrast, SeNPs without anisomycin easily aggregated
owing to the high surface energy of SeNPs, and precipi-
tated in the aqueous solution with an average diameter
of approximately 110 nm. Particle size, distribution, and
zeta potential of SeNPs@Am were measured to examine
effects of anisomycin on stability and surface properties
of SeNPs. Our data indicated that the presence of aniso-
mycin dramatically decreased the average diameter of
SeNPs from 125 to 63 nm (Fig. 3g, h). After surface
modification with anisomycin, the zeta potential of parti-
cles was obviously decreased from −11.5 to −24.4 mV,
suggesting that the SeNPs@Am exhibited higher stability
than SeNPs (Fig. 3i). In addition, we found that SeNP-
s@Am kept stable during 8 days in water solution. In
contrast, the particle size of SeNPs alone dramatically
increased up to ~300 nm after 8 days (Fig. 3j).
EDS analysis showed presence of a signal from Se
atom (69.8 %), together with N (1.4 %), C (22.6 %), and
O (6.2 %) atoms from anisomycin molecules. The presencetrations of Se, respectively. b The average diameter of above
Fig. 2 a Distribution of SeNPs@Am with various size at different reaction concentrations of anisomycin, respectively. b The average diameter of
above SeNPs@Am, respectively
Fig. 3 Characterization of SeNPs and SeNPs@Am. a–c, d–f TEM images of SeNPs and SeNPs@Am, respectively. g, h Particle size and distribution
of SeNPs and SeNPs@Am, respectively. i Zeta potential of SeNPs and SeNPs@Am. j Particle size growth of SeNPs and SeNPs@Am during 30 days
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conjugated with anisomycin (Fig. 4a). Based on the results
from EDS, the representative chemical formula for SeNP-
s@Am is derived as (Se9Am)n. FTIR spectroscopy was fur-
ther used to find out whether there was a formation of
chemical bonds between anisomycin and Se. In the
spectrum of anisomycin, the peaks at 2938 and 1376 cm−1
were attributed to the stretching vibrations of C−C and
C−N, respectively. The appearance of the above peaks in
the spectrum of SeNPs@Am suggested the presence of
anisomycin on the surface of SeNPs (Fig. 4b). XPS was
also recorded for interaction between SeNPs@Am and
anisomycin. The N 1 s peak at about 400 eV in theFig. 4 Chemical composition and structure characterization of SeNPs@Am.
Am. c XPS spectra of SeNPs@Am and Am. d Se 3d spectra of SeNPs@Am a
SeNPs@Am and Amspectrum of SeNPs@Am showed that anisomycin was
conjugated to the SeNPs (Fig. 4c). The peaks of Se 3d5/2
and 3d3/2 also shifted from 55.2 and 56.05 eV (SeNPs) to
55.15 and 56.0 eV (SeNPs@Am), respectively, suggesting a
strong interaction between anisomycin and Se nanoparti-
cles (Fig. 4d). Meanwhile, the spectrum of N 1 s and O 1 s
peaks in SeNPs@Am both split into two, respectively
(Fig. 4e, f ). Therefore, these results further confirmed the
formation of Se–N and Se–O bonds in SeNPs@Am.
Enhanced Cellular Uptake of SeNPs@Am
Intracellular uptake of nanomaterial-based drugs is a key
factor that usually contributes to drug cytotoxicity [23].a EDS analysis of SeNPs@Am. b FTIR spectra of SeNPs, SeNPs@Am and
nd Am. e N 1 s spectra of SeNPs@Am and Am. f O 1 s spectra of
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take of SeNPs@Am with various sizes by HepG2 cells
was examined. As shown in Fig. 5, cellular uptake is
particle-size-dependent ranging from 56 to 185 nm and
the maximum uptake by HepG2 cells occurs at a nano-
particle size of 56 nm, suggesting that the size of parti-
cles plays a very important role in the cellular uptake. It
has been reported that nanoparticles with the diameter
of ~55 nm have the fastest wrapping time and the
receptor-ligand interaction can produce enough free en-
ergy to drive the nanoparticles into the tumor cells. This
minimum wrapping time led to more accumulation of
the ~55-nm nanoparticles into the tumor cells [24].
To investigate cellular uptake effectiveness in HepG2
cells, a short-term particle endocytosis test was visually
carried out using coumarin-6-loaded SeNPs@Am. Green
fluorescence from coumarin-6-loaded SeNPs@Am pene-
trating into HepG2 cells was enhanced in a dose-
dependent manner, following incubation of the cells with
the labeled SeNPs@Am for 4 h (Fig. 6a). Consistent with
other reports, SeNPs@Am mainly accumulated in cyto-
plasm, but was not detected in the nucleus, indicating
that the nuclei were not the cellular target of SeNPs@Am
[25]. The intracellular SeNPs@Am increased in a time-
dependent manner. Cellular uptake of SeNPs@Am ap-
peared at 15 min, and then the intracellular SeNPs@Am
gradually increased during 2 h treatment (Fig. 6b). It was
worth mentioning that the cells treated with SeNPs@Am
exhibited markedly morphologic changes, where lots of
cells became round and adherent cells tended to be de-
tached. The morphological changes in HepG2 cells might
be due to the cytotoxicity of cellular accumulation of
SeNPs@Am.
A quantitative analysis of cellular uptake was con-
ducted by ICP-MS [26]. Internalization of SeNPs and
SeNPs@Am was investigated in HepG2 and HUVEC-12
cells, respectively. Intracellular SeNPs@Am concentrationsFig. 5 Size-dependent cellular uptake effciency of SeNPs@Am by
HepG2 cells. Values expressed are means ± SD of triplicatewere increased in HepG2 cells in a time- or dose-
dependent manner (Fig. 6c). As shown clearly in Fig. 6d,
the cellular uptake ability in HepG2 cells was greater in
comparison with that in HUVEC-12 cells. The higher cellu-
lar uptake of SeNPs@Am in HepG2 cells may be due to its
favorable membrane permeability.
The above datum indicate that nanoparticles SeNP-
s@Am with 56 nm in size are well uptaken by HepG2
cells and are the most suitable candidates for further
studies in biological application.
Localization, Uptake Channel, and Release of SeNPs@Am
Intracellular localization of SeNPs@Am was explored by
lyso tracker red and DAPI for staining of lysosome and
nucleus, respectively [27]. The merged images clearly
showed that most of SeNPs@Am resided in the lyso-
somes, followed by a gradual dosage increasement dur-
ing 4 h of treatment (Fig. 7a). This result verifies that
lysosome is a main organelle target for SeNPs@Am.
Controlled and sustained drug release is very import-
ant for drug delivery systems [28]. Generally speaking,
pH value in tumor tissue is lower than normal, which is
attributed to lactic acid produced due to hypoxia and
acidic intracellular organelles. Thus, we carried out drug
release kinetic measurement at both pH 7.4 and 5.4 to
mimic physiological and lysosomal pH (Fig. 7b). Aniso-
mycin release from SeNPs@Am was much lower at pH
7.4 (45.4 %) than at pH 5.4 (81.0 %) for 48 h. At lower
pH, more anisomycin molecules were protonated, which
resulted in a weaker binding force between anisomycin
and SeNPs. This initial rapid release of anisomycin can
be partly due to the adsorption of drug on the surface of
nanoparticles.
Endocytosis is one of the most important entry mech-
anisms for nanoparticles [29]. In living cells, the endo-
cytosis involves three major pathways, including
caveolae-mediated endocytosis, macropinocytosis, and
clathrin-mediated endocytosis. Several specific endocyto-
sis inhibitors, such as monensin, colchicine, and sucrose,
were used to elucidate cellular uptake channels and
endocytosis mechanisms of SeNPs@Am in HepG2 cells.
Treatments with NaN3 and DOG, or at 4 °C, dramatically
decreased the cellular uptake of SeNPs@Am, demonstrat-
ing that SeNPs@Am enters HepG2 cells via energy-
dependent endocytosis. Cellular uptake of SeNPs@Am
was decreased markedly by colchicine and sucrose endo-
cytosis inhibitors, indicating that SeNPs@Am enters the
cells via macropinocytosis and/or clathrin-mediated endo-
cytosis pathways (Fig. 7c).
In vitro Cytotoxicity of SeNPs@Am
Cytotoxicity of SeNPs@Am against HepG2 or HUVEC-
12 cells was investigated by MTT assay. Reducing cell
survival to around 36.4 or 54.5 % (Fig. 8a), 0.2 μM of
Fig. 6 Cellular uptake of SeNPs@Am. a Fluorescence microscope images show the internalization of coumarin-6-loaded SeNPs@Am (green
fluorescence) in HepG2 cells. b Real-time imaging for HepG2 cells treated with coumarin-6-loaded SeNPs@Am. The upper panel is merged
images of the nanoparticles and nuclei, and the lower panel is DIC images. Magnification, ×400. c Time- and dose-dependent cellular uptake
efficiency of SeNPs@Am by HepG2 cells. d Dose-dependent cellular uptake efficiency of SeNPs@Am by HUVEC-12 and HepG2 cells. Values
expressed are means ± SD of triplicate
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viability of HepG2 cells in a dose-dependent manner.
However, bare SeNPs as a carrier was slightly cytotoxic
to HepG2 cells even at a dose of 16 μM (Additional file
1: Figure S1 in supporting information). The data indi-
cates that SeNPs as a drug delivery system obviously en-
hances the anticancer activity of anisomycin on HepG2
cells. This can be explained by the fact that the con-
trolled and sustained drug release of SeNPs@Am led to
a considerably higher intracellular concentration of drug
in HepG2 cells with a highly efficient anticancer activity.
Meanwhile, SeNPs@Am showed a weak ability to kill
HUVEC-12 (Fig. 8b). The result may be attributed to
greater cellular uptake ability in HepG2 cells in compari-
son with HUVEC-12. The high activity of SeNPs@Am
under low concentration supports its future medical
applications.Influence of SeNPs@Am on Cell Cycle and Apoptosis
Flow cytometry was employed to study the impact of
SeNPs@Am on cell cycle progression. HepG2 cells were
stimulated with SeNPs@Am for 24 h and subjected to
flow cytometry for cell cycle analysis [30]. The untreated
cells were mainly in the G0/G1 phase, whereas the SeNP-
s@Am-treated cells cycled into the sub-G1 phase in a
dose-dependent manner, suggesting that SeNPs@Am sig-
nificantly induces HepG2 cell apoptosis. Meanwhile,
SeNPs@Am resulted in increasement of the cells at the
G0/G1 phase and decreasement at the S-phase and G2/
M-phase with the increasement of the concentrations of
SeNPs@Am. However, little change was observed in ani-
somycin or SeNPs groups (Fig. 8c).
To quantify apoptosis in HepG2 cells triggered by
SeNPs@Am, the cells were analyzed by Annexin V-FITC
and PI dual staining. The apoptotic rate of HepG2 cells
Fig. 7 Colocalization of SeNPs@Am and lysosomes in HepG2 cells. a HepG2 cells were treated with lysosomal marker lyso tracker red (red fluorescence)
and coumarin-6-loaded SeNPs@Am (green fluorescence) at 37 oC for different time and visualized under a fluorescence microscope (magnification, ×400).
b In vitro release profile of Am from SeNPs@Am in RPMI-1640 medium with 10 % fetal bovine serum. Am concentrations were determined by
HPLC analysis. c Cellular amount of Se in HepG2 cells after 4 h of incubation with SeNPs@Am. The cells were incubated for 4 h either at 37 °C
(control) or at 4 °C. Prior to the incubation with SeNPs@Am, the cells were pretreated with specific endocytosis inhibitors for 1 h. **p < 0.01,
***p < 0.001 vs. the control
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in which the early- and late-stage apoptotic rates of
HepG2 cells treated with 0.2 μM of SeNPs@Am reached
10.81, and 13.34 %, respectively. However, the early- and
late-stage apoptotic rates of HepG2 cells treated with
0.2 μM of anisomycin only reached 4.63 and 10.23 %, re-
spectively (Fig. 8d). Therefore, SeNPs@Am exhibits
greater ability to arrest the cell cycle and induce the apop-
tosis of HepG2 cells than anisomycin-free SeNPs or aniso-
mycin alone. The SeNPs@Am-induced cell apoptosis was
further determined by a TUNEL-DAPI assay [31]. HepG2
cells were exposed to 0.1 or 0.2 μM of SeNPs@Am for
24 h to display apoptotic properties, such as chromatin
condensation, nuclear condensation, and formation of
apoptotic bodies (Fig. 8e). These results support that
SeNPs@Am represses HepG2 cell growth mainly through
inhibiting the cell proliferation, arresting the cell cycle
progression, and promoting the cell apoptosis.
SeNPs@Am Precludes the Motility and Migration of
HepG2 Cells
A wound-healing assay was carried out to explore effect
of SeNPs@Am, anisomycin, and SeNPs on HepG2 cellmotility (Fig. 9a). Compared with the control, wound
healing was obviously suppressed by SeNPs@Am or
anisomycin, whereas SeNPs had negligible effect on
cell migration. At 24 h, the wounds of the control,
SeNPs@Am, and anisomycin groups were healed
about 67.03 ± 1.7 %, 21.9 ± 3.1 %, and 42.7 ± 2.6 %, re-
spectively (Fig. 9b). The results show that the HepG2
cell aggression was largely inhibited by SeNPs@Am,
and SeNPs@Am is more effective than the free
anisomycin.
A transwell filter assay was employed to further
analyze tumor cell migration [32]. HepG2 cells can mi-
grate across the pored filter membrane on the transwell
[33]. At 24 h, the seeded cells migrated to the lower side
of the filter membrane. SeNPs did not affect HepG2 cell
migration. However, in the presence of SeNPs@Am or
anisomycin, the cell migration was significantly inhib-
ited, with the inhibition rate of 52.4 ± 3.4 % and 30.6 ±
2.5 %, respectively (Fig. 9c, d). The results of the trans-
well assay are concordant with the wound-healing assay,
suggesting that SeNPs@Am is significantly superior to
the free anisomycin to preclude the motility and migra-
tion of HepG2 cells.
Fig. 8 SeNPs@Am alters HepG2 cell biobehaviors via affecting the cell proliferation, cycle and apoptosis. a, b Cell viability in HepG2 and HUVEC-12 cells
were determined by the MTT assay after their exposure to SeNPs@Am and Am. c Cell cycle distribution was analyzed by flow cytometry.
d The apoptotic proportion of cells was analyzed by flow cytometry. e Representative photomicrographs of DNA fragmentation and nuclear
condensation induced by SeNPs@Am were detected by TUNEL-DAPI co-staining assay at 24 h post the treatment. Amplification, ×400
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Cycle-Associated Proteins
Cell cycle arrest is a major event to block tumor pro-
gression and metastasis. Cell cycle progression is
mainly controlled by action of various types of cyclins
and cyclin-dependent protein kinase (CDKs) [34]. Ex-
pressions of CDK inhibitors, such as p21, p27, and p53,
regulate progression of cell cycle in G1 phase. As
shown in Fig. 10a, the protein levels of phosphorylated
CDK2 (an active form of CDK2) were down-regulated
following treatment with 0.2 μM SeNPs@Am. On the
other hand, the protein levels of p21/phosphorylated
p21, p27/phosphorylated p27, and P53/phosphorylated
p53 were significantly up-regulated. It is reported that
the p21 cyclin-dependent kinase inhibitor gene can be
activated by p73, and high-level expression of p21 can
down-regulate ICBP90 through an ubiquitination-dependent protease degradation pathway [35, 36].
Fig. 10a shows that the expression of phosphorylated
p73 was dramatically increased by SeNPs@Am, but the
expression of the ICBP90 was decreased. These results
indicate that SeNPs@Am causes cell cycle arrest
through influencing expressions of the CDKs and re-
lated CDK inhibitors. The expression level of proteins
from the SeNPs@Am-treated HepG2 cells were higher
than that in the anisomycin-treated cells except p-
CDK2 protein, suggesting SeNPs@Am exhibited greater
activity than anisomycin to affect the protein expres-
sion. However, SeNPs as a drug carrier had little effects
on protein expression.
A Rb pathway can suppress a transcriptional process
of genes necessary for transition from G1- to S-phase.
Phosphorylation of the Rb protein may be induced by
cyclin D-CDK-4/6 complexes. On the contrary, its
Fig. 9 Wound edges were marked with lines. Amplification, ×100. a The wound-healing width was observed at the indicated time after the treatment
of SeNPs@Am. b The cell motility of the control and treated HepG2 cells was quantitatively analyzed at 24 h. c The effect of SeNPs@Am, Am, and
SeNPs on the migration of HepG2 cells. d The inhibition rate of migration of control, SeNPs@Am, Am, and SeNPs, respectively. Data represent the
mean ± SD of three independent experiments. **p < 0.01, ***p < 0.001 vs. the control
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Rb protein facilitates the release of a transcription factor
E2F1, leading to S-phase entry [37, 38]. As shown in
Fig. 10b, Rb/phosphorylated Rb, p16, and E2F1 proteins in
the SeNPs@Am-treated, anisomycin-treated, or SeNPs-
treated HepG2 cells had little changes, suggesting that these
proteins do not take part in the action of SeNPs@Am,
anisomycin, or SeNPs on HepG2 cell biobehaviors.
Impact of SeNPs@Am on the Expressions of
Apoptosis-Associated Proteins
Caspase-3, caspase-8, and caspase-9 in caspase cascade
signaling pathway are considered to be importantproteases that can trigger cell apoptosis after cleaved
[39]. Thus, we detected expressions of their activating
forms, i.e., cleaved-caspase-3, cleaved-caspase-8, and
cleaved-caspase-9 in the free treated, SeNPs@Am-
treated, Am-treated, and SeNPs-treated HepG2 cells.
SeNPs@Am can significantly induce the expressions
of cleaved-caspase-3, cleaved-caspase-8, and cleaved-
caspase-9 in HepG2 cells, and the activity of SeNPs@Am
is stronger than that of anisomycin. SeNPs had little ef-
fects on them (Fig. 10c). Therefore, it is speculated that
the activation of the cell cycle-regulating signals by
SeNPs@Am may be connected to the activation of the
caspase cascade signals.
Fig. 10 Effects of SeNPs@Am, Am, and SeNPs on the expression of cell cycle-related proteins. a p-CDK2, p21/pp21, p27/pp27, p53/pp53, p73/
pp73, ICBP90. b Rb/pRb, p16, E2F1. c apoptosis-associated proteins cleaved-caspase-3, cleaved-caspase-8, and cleaved-caspase-9 in HepG2 cells
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In summary, we have developed a drug delivery system
based on selenium nanoparticles to successfully make a
novel nanoparticle drug SeNPs@Am. It involves some key
issues in the field of drug delivery. The SeNPs@Am with
different sizes was prepared by adjusting the concentra-
tions of reaction substrates. The SeNPs@Am of 56 nm in
size presents the maximum cellular uptake in HepG2
cells. SeNPs@Am exhibits greater abilities to inhibit cell
proliferation, arrest cell cycle, induce cell apoptosis, and
block cell motility and migration than anisomycin does.
Our results reveal that SeNPs@Am can inhibit human he-
patocellular carcinoma multi-biobehaviors even in low
concentration through activation of the P53/P73/P21/P27
signaling with inhibition of CDK-2 and ICBP90, and the
caspase signaling, indicating that it may be a promising
drug for hepatocellular carcinoma.Additional file
Additional file 1: Figure S1. Cell viability in HepG2 cells determined by
the MTT assay after their exposure to SeNPs.
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